New hope for eczema sufferers: dupilumab boosts skin barrier in chinese patients
NCT ID NCT05624112
First seen Oct 01, 2025 · Last updated May 14, 2026 · Updated 33 times
Summary
This study looked at how dupilumab, a medication for moderate to severe eczema (atopic dermatitis), improves the skin's barrier function in Chinese patients. 44 participants received the drug for 16 weeks, and researchers measured water loss from the skin to see how well the barrier was working. The goal was to understand if dupilumab helps repair the skin's protective layer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dermatology Hospital of Southern Medical University (Guangdong Provincial Dermatology Hospital)
Guangzhou, Guangdong, 510091, China
Conditions
Explore the condition pages connected to this study.